VERA - NASDAQ

Vera Therapeutics, Inc.

VERA·NASDAQ

$31.27

-7.9%

HealthcareBiotechnology

Vera Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases in the United States. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase IIb clinical trial for patients with immunoglobulin A nephropathy. It is also developing MAU868, a monoclonal antibody for the treatment of BK viremia infections and is under Phase 2 clinical trial. The company was formerly known as Trucode Gene Repair, Inc. and changed its name to Vera Therapeutics, Inc. in April 2020. Vera Therapeutics, Inc. was incorporated in 2016 and is headquartered in Brisbane, California.

Statements Value Model

At a Glance

Live Snapshot

Market Cap$2.24B

EPS-4.6600

P/E Ratio-6.71

Earnings Date08/04/2026

734.73M

Assets

12%

3Y+459.0%

5Y+1247.0%

10Y+13554.0%

130.21M

Total Liabilities

66%

3Y+139.0%

5Y-10.0%

10Y+211.0%

604.52M

Total Equity

3Y+686.0%

5Y-777.0%

10Y-1754.0%

Vera Therapeutics, Inc. Funding & Solvency Profile

VERA · NASDAQ

Current Assets

Cash & Cash Equivalents354.73M

Net Receivables3.29M

Inventory0.00

Other Current Assets11.01M

Total Current Assets729 M

Non-Current Assets

Property, Plant & Equipment1.92M

Goodwill & Intangible Assets0.00

Long-Term Investments0.00

Other Non-Current Assets3.93M

Total Non-Current Assets6 M

Total Assets

734.73M

Financial Health Analysis

Current Ratio

13.64x

Excellent liquidity position. The company can easily cover its short-term obligations with substantial cushion.

Debt-to-Equity Ratio

0.22x

Conservative capital structure. The company relies primarily on equity financing, indicating low financial risk.

Working Capital

675 M

Strong working capital position provides significant operational flexibility and financial cushion.

Asset Composition

99% Current

Asset-light business model with high liquidity. Majority of assets are easily convertible to cash.

Financial Health Insight

Strong financial foundation: Excellent liquidity combined with conservative leverage suggests the company is well-positioned to weather economic uncertainties and fund growth opportunities.

Vera Therapeutics, Inc. Balance Sheet

VERA • NASDAQ

Vera Therapeutics, Inc. Balance Sheet	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020	Dec 2019
ASSETS
CURRENT ASSETS
Cash and Cash Equivalents	354.7M	92.6M	45.7M	43.5M	79.7M	53.7M	3.2M
Short-Term Investments	359.9M	548.2M	115M	71.2M	0.0	0.0	0.0
Cash & Short-Term Investments	714.6M	640.9M	160.7M	114.7M	79.7M	53.7M	3.2M
Net Receivables	3.3M	3.8M	0.0	0.0	0.0	52K	0.0
Accounts Receivables	0.0	3.8M	0.0	0.0	0.0	0.0	0.0
Other Receivables	3.3M	0.0	0.0	0.0	0.0	52K	0.0
Prepaids	0.0	5.7M	8.1M	10.3M	2.4M	113K	366K
Other Current Assets	11M	913K	3.2M	719K	480K	442K	4K
Total Current Assets	728.9M	651.2M	172M	125.7M	82.5M	54.3M	3.6M
NON-CURRENT ASSETS
Property, Plant, and Equipment (Net)	1.9M	4.3M	3M	5.2M	0.0	0.0	1.4M
Long-Term Investments	0.0	0.0	11K	58K	867K	0.0	0.0
Other Non-Current Assets	3.9M	131K	471K	455K	344K	293K	422K
Total Non-Current Assets	5.9M	4.5M	3.5M	5.7M	1.2M	293K	1.8M
Total Assets	734.7M	655.7M	175.5M	131.4M	83.7M	54.6M	5.4M
LIABILITIES
CURRENT LIABILITIES
Total Payables	21.9M	7.9M	11.1M	14.8M	2.4M	909K	342K
Accounts Payable	21.9M	7.7M	11.1M	12M	1.4M	909K	342K
Other Payables	0.0	217K	0.0	2.8M	1M	0.0	0.0
Accrued Expenses	0.0	16M	3.9M	8.2M	4.9M	535K	376K
Short Term Debt	549K	0.0	0.0	0.0	0.0	0.0	0.0
Capital Lease Obligations (Current)	0.0	1.5M	2.4M	2.6M	0.0	2K	122K
Other Current Liabilities	31M	0.0	4.8M	0.0	377K	960K	220K
Total Current Liabilities	53.5M	25.4M	22.3M	25.6M	7.7M	2.4M	1.1M
NON-CURRENT LIABILITIES
Long Term Debt	76.8M	50.7M	49.9M	24.8M	4.9M	0.0	0.0
Other Non-Current Liabilities	0.0	0.0	286K	286K	1.5M	141.5M	40.9M
Total Non-Current Liabilities	76.8M	53.2M	51.6M	28.9M	6.5M	141.5M	40.9M
Capital Lease Obligations	0.0	4M	3.8M	6.5M	0.0	2K	132K
Total Liabilities	130.2M	78.5M	73.9M	54.5M	14.2M	143.9M	41.9M
SHAREHOLDERS' EQUITY
Common Stock	71K	64K	44K	28K	21K	0.0	0.0
Additional Paid-In Capital	1.4B	1B	410.5M	290.2M	193.6M	2.1M	1.5M
Retained Earnings	-760.9M	-461.3M	-309.1M	-213.1M	-124.1M	-91.4M	-38M
Accumulated Other Comprehensive Income/Loss	786K	393K	251K	-224K	0.0	0.0	0.0
Total Stockholders' Equity	604.5M	577.2M	101.7M	76.9M	69.6M	-89.3M	-36.5M
Total Equity	604.5M	577.2M	101.7M	76.9M	69.6M	-89.3M	-36.5M
SUMMARY
Total Liabilities & Equity	734.7M	655.7M	175.5M	131.4M	83.7M	54.6M	5.4M
Total Investments	359.9M	548.2M	115M	71.3M	867K	0.0	0.0
Total Debt	77.3M	54.6M	53.7M	31.3M	4.9M	2K	132K
Net Debt	-277.4M	-38M	8M	-12.2M	-74.8M	-53.7M	-3.1M
Shares Outstanding	63,928,061	63,928,061	63,928,061	63,928,061	63,928,061	63,928,061	63,928,061

SEC Filings

VERA - Filing history and reports

Filing Type	Filing Date	Period Ending	Fiscal Year	Actions
8-K 8-K 2026 N/A	June 02, 2026	June 02, 2026	2026	View Filing
8-K 8-K 2026 N/A	May 26, 2026	May 21, 2026	2026	View Filing
10-Q 10-Q 2026 Q1 Q1	May 07, 2026	March 31, 2026	2026	View Filing
8-K 8-K 2026 N/A	May 07, 2026	May 07, 2026	2026	View Filing
DEF 14A DEF 14A 2026 N/A	April 09, 2026	May 21, 2026	2026	View Filing
8-K 8-K 2026 N/A	March 09, 2026	March 05, 2026	2026	View Filing
8-K 8-K 2026 N/A	February 26, 2026	February 26, 2026	2026	View Filing
10-K 10-K 2025 FY FY	February 26, 2026	December 31, 2025	2025	View Filing
8-K 8-K 2025 N/A	December 18, 2025	December 16, 2025	2025	View Filing
8-K 8-K 2025 N/A	December 10, 2025	December 09, 2025	2025	View Filing

Showing 1 to 10 of 90 filings

Related Guides

Blog Categories

Continue your VERA research with focused valuation guides.

Fundamentals

Decode statement quality and operating durability.

Accounting

Interpret line items with cleaner analytical framing.

Forecasting

Translate historical performance into forward scenarios.

Reference

Use practical frameworks for statement-led valuation.

Research Paths

Pick your next lens

Snapshot

Start with context, operating signals, and key market metrics.

Value Model

Stress test fair value across bear, base, and bull assumptions.

Statements

Validate revenue quality, margins, and balance sheet durability.

Earnings Call

Read management commentary and compare it with reported outcomes.

Dividends

Check payout sustainability and long-term distribution behavior.

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.